BACKGROUND
The markers of bone remodelling, such as serum osteocalcin, may be used to assess osteoporosis and to predict the fracture risk in elderly persons, especially in women. The bone mineral density which reflects the bone mass and strength, also predicts osteoporotic related hip fractures. So, this work highlights the association between the bone turnover and the bone mass and strength.
AIM
To assess the association between the biochemical markers of bone remodeling and osteocalcin with the bone mineral density in non osteoporotic and osteoporotic women among post menopausal subjects.
MATERIALS AND METHODS
Sixty postmenopausal women whose ages ranged from 55-65 years included in this study, were further divided into group 1 (thirty non osteoporotic subjects) and group 2 (thirty osteoporotic subjects). For all the subjects, serum osteocalcin was measured by ELISA. BMD was measured by the Dual Energy X- Ray Absorptiometry (DXA) scan. The women with osteoporosis were diagnosed, based on the T- score of the bone mineral density, by the DXA scan. The Student's "t" test was performed between the variables of both the groups and a correlation test was also performed between osteocalcin and BMD by using SPSS.
RESULTS
A negative correlation was found between the osteocalcin level and the bone mineral density in post menopausal women. The mean values of both serum osteocalcin and BMD between the osteoporotic and the non osteoporotic subjects were statistically significant.
CONCLUSION
An increased bone turnover coincides with the trabecular deterioration in osteoporotic women of the post menopausal age group. A combination of biochemical markers and BMD may be a better predictor of the fracture risk than when it was assessed by either alone. The biochemical markers of the bone turnover cannot be a substitute for the serial BMD measurement, but they may be useful when they are considered in conjunction with the BMD measurement.
[1]
W. Gruber,et al.
Biochemical markers in menopausal women.
,
1997,
Scandinavian journal of clinical and laboratory investigation. Supplementum.
[2]
B. Dijkmans,et al.
Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
,
2007,
The Journal of rheumatology.
[3]
M. Moyad.
Preventing male osteoporosis: prevalence, risks, diagnosis and imaging tests.
,
2004,
The Urologic clinics of North America.
[4]
C. Christiansen,et al.
High bone turnover is associated with low bone mass in both pre- and postmenopausal women.
,
1996,
Bone.
[5]
R. Civitelli,et al.
Bone turnover markers: understanding their value in clinical trials and clinical practice
,
2009,
Osteoporosis International.
[6]
P. Delmas,et al.
Bone quality--the material and structural basis of bone strength and fragility.
,
2006,
The New England journal of medicine.
[7]
M. Iki,et al.
Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study
,
2004,
Osteoporosis International.